IP Library Granted Patent US 8,227,608
Granted Patent B2
US 8,227,608 · App. 12/586,842 · Granted Jul 24, 2012

Processes for increasing the yield of opiate alkaloid derivatives

Assignee: Mallinckrodt LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,608
App. No.
12/586,842
Granted
Jul 24, 2012
Kind
B2
Abstract

The present invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for recycling impurities into useful intermediates during the synthesis of opiate alkaloids.

Claims (42)

1. A process for the preparation of a compound of Formula (II), the process comprising contacting a compound of Formula (I) with a hydrolysis agent to form the compound of Formula (II):

wherein:

R 1 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 2 , and R 3 are independently selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 4 and R 5 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 7 , and {—}OR 7 ;

R 6 is independently selected from the group consisting of hydrogen, a protecting group, hydrocarbyl, and substituted hydrocarbyl; and

X is oxygen, and

wherein the molar ratio of the compound of Formula (I) to the hydrolysis agent is from about 1:5 to about 1:9 and wherein the molar yield of Formula (II) is at least 65%.

2. The process of claim 1 , wherein R 1 , R 6 , R 8 , and R 9 are alkyl or substituted alkyl; and R 2 , R 3 , R 4 , and R 5 are hydrogen.

3. The process of claim 1 , wherein the hydrolysis agent is a compound having a pKa of greater than about 12.0.

4. The process of claim 1 , wherein R 1 , R 6 , R 8 , and R 9 are alkyl or substituted alkyl; the hydrolysis agent is a hydroxide of a group 1 or group 2 metal; the reaction is conducted in the presence of an organic solvent; the reaction is conducted at a pH of at least about 12.0; and the reaction is conducted at a temperature from about 150° C. to about 200° C.

5. The process of claim 4 , wherein the hydrolysis agent is potassium hydroxide.

6. The process of claim 1 , wherein the optical activity of the compound of Formula (I) or (II) is selected from the group consisting of (+), (−), and combinations thereof; the configuration of each of C5 and C6 is R; and the configuration of C7, C9, C13, and C14, respectively, is selected from the group consisting of may be RRSS, RSRR, SRSS, and SSRR, provided that the C15 and the C16 carbons are both either on the alpha face or the beta face of the molecule.

7. A process for the preparation of a compound of Formula (IIa), the process comprising contacting a compound of Formula (Ia) with a hydrolysis agent to form the compound of Formula (IIa):

wherein the molar ratio of the compound of Formula (Ia) to the hydrolysis agent is from about 1:5 to about 1:9 and wherein the molar yield of Formula (IIa) is at least 65%.

8. The process of claim 7 , wherein the hydrolysis agent is a compound having a pKa of greater than about 12.0.

9. The process of claim 7 , wherein the hydrolysis agent is a hydroxide of a group 1 or group 2 metal; the reaction is conducted in the presence of an organic solvent; the reaction is conducted at a pH of at least about 12.0; and the reaction is conducted at a temperature from about 150° C. to about 200° C.

10. The process of claim 9 , wherein the hydroxide is potassium hydroxide.

11. The process of claim 7 , wherein the optical activity of the compound of Formulas (Ia) or (IIa) is selected from the group consisting of (+), (−), and combinations thereof; the configuration of each of C5 and C6 is R; and the configuration of C7, C9, C13, and C14, respectively, is selected from the group consisting of may be RRSS, RSRR, SRSS, and SSRR, provided that the C15 and the C16 carbons are both either on the alpha face or the beta face of the molecule.

12. A process for the preparation of a compound of Formula (II), the process comprising:

a) contacting a compound of Formula (Ib) with a first hydrolysis agent to form the compound of Formula (II) and a compound of Formula (I):

wherein:

R 1 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, hydrocarbyl, and substituted hydrocarbyl;

R 4 and R 5 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 7 , and {—}R 7 ;

R 6 is independently selected from the group consisting of hydrogen, a protecting group, hydrocarbyl, and substituted hydrocarbyl; and X is oxygen; and

b) isolating the compound of Formula (I); and

c) contacting the isolated compound of Formula (I) with a second hydrolysis agent to form additional amounts of the compound of Formula (II), wherein the molar ratio of the compound of Formula (Ib) to the first hydrolysis agent is from about 1:9 to about 1:15 and the molar ratio of the compound of Formula (I) to the second hydrolysis agent is from about 1:5 to about 1:9.

13. The process of claim 12 , wherein R 1 , R 6 , R 8 , and R 9 are alkyl or substituted alkyl; and R 2 , R 3 , R 4 , and R 5 are hydrogen.

14. The process of claim 12 , wherein the first and second hydrolysis agents are each a compound having a pKa of greater than about 12.0.

15. The process of claim 12 wherein R 1 , R 6 , R 8 , and R 9 are alkyl or substituted alkyl; the first and second hydrolysis agents are each a hydroxide of a group 1 or group 2 metal; the reactions in steps (a), (b) and (c) are conducted in the presence of an organic solvent; the reaction in step (b) further comprises an addition of water; the reactions in steps (a), (b) and (c) are conducted at a pH of at least about 12.0; and the reactions in steps (a) and (b) are conducted at a temperature from about 150° C. to about 200° C.

16. The process of claim 12 , wherein the amount of the compound of Formula (I) formed is from about 1% to about 10% by weight of the total amount of the compound of Formula (II) and the compound of Formula (I) formed in step (a); and the molar yield of the compound of Formula (II) in step (a) is greater than about 70%; and the molar yield of the compound of Formula (II) in step (c) is greater than about 70%.

17. The process of claim 12 , wherein the optical activity of the compound of Formulas (I), (Ib), or (II) is selected from the group consisting of (+), (−), and combinations thereof; the configuration of each of C5 and C6 is R; and the configuration of C7, C9, C13, and C14, respectively, is selected from the group consisting of may be RRSS, RSRR, SRSS, and SSRR, provided that the C15 and the C16 carbons are both either on the alpha face or the beta face of the molecule.

18. A process for the preparation of a compound of Formula (IIa), the process comprising:

a) contacting a compound of Formula (Ic) with a first hydrolysis agent to form the compound of Formula (IIa) and a compound of Formula (Ia):

b) isolating the compound of Formula (Ia); and

c) contacting the isolated compound of Formula (Ia) with a second hydrolysis agent to form additional amounts of the compound of Formula (IIa), wherein the molar ratio of the compound of Formula (Ic) to the first hydrolysis agent is from about 1:9 to about 1:15 and the molar ratio of the compound of Formula (Ia) to the second hydrolysis agent is from about 1:5 to about 1:9.

19. The process of claim 18 , wherein the first and second hydrolysis agents are each a compound having a pKa of greater than about 12.0.

20. The process of claim 18 , wherein the first and second hydrolysis agents are each a hydroxide of a group 1 or group 2 metal; the reactions in steps (a), (b) and (c) are conducted in the presence of an organic solvent; the reaction of step (b) further comprises an addition of water; the reactions in steps (a), (b) and (c) are conducted at a pH of at least about 12.0; and the reactions in steps (a) and (c) are conducted at a temperature from about 150° C. to about 200° C.

21. The process of claim 20 , wherein the first and second hydrolysis agents are each potassium hydroxide.

22. The process of claim 18 , wherein the amount of the compound of Formula (Ia) formed is from about 1% to about 10% by weight of the total amount of the compound of Formula (IIa) and the compound comprising Formula (Ia) formed in step (a); and the molar yield of the compound of Formula (IIa) in step (a) is greater than about 70% and the molar yield of compound of Formula (IIa) in step (c) is greater than 70%.

23. The process of claim 18 , wherein the optical activity of the compound of Formulas (Ia), (Ic), or (IIa) is selected from the group consisting of (+), (−), and combinations thereof; the configuration of each of C5 and C6 is R; and the configuration of C7, C9, C13, and C14, respectively, is selected from the group consisting of may be RRSS, RSRR, SRSS, and SSRR, provided that the C15 and the C16 carbons are both either on the alpha face or the beta face of the molecule.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2009
From: ALLEN, BRENDA E.
To: MALLINCKRODT INC.
Reel/Frame 023396/0057 →
Continuity (2)
Provisional Application 61194680 · Sep 30, 2008
Related Publication 20100081814A1 · Apr 1, 2010